Your session is about to expire
← Back to Search
Dietary Supplement
RGMA001 for Non-alcoholic Fatty Liver Disease
N/A
Waitlist Available
Led By John Poulos, MD
Research Sponsored by Biovil Research Group, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male and female patients age 18 years and older.
A clinical or histologic or radiographic diagnosis of NAFLD.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 weeks
Awards & highlights
Study Summary
A research study of a compound containing vitamin E, silymarin and carnitine, three over the counter supplements. The investigators hope to learn if the new supplement can safely and successfully treat fatty liver disease or Non Alcoholic Fatty Liver Disease (NAFLD).
Eligible Conditions
- Non-alcoholic Fatty Liver Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Efficacy
Secondary outcome measures
Safety
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: RGMA001Active Control1 Intervention
Proprietary blend of Vitamin E, Silymarin, and Carnitine.
Group II: Sugar PillPlacebo Group1 Intervention
No treatment.
Find a Location
Who is running the clinical trial?
Biovil Research Group, LLCLead Sponsor
John Poulos, MDPrincipal InvestigatorCumberland Research Associates
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger